FDA Continues to Accelerate Availability of COVID-19 Tests

Alston & Bird

The Food and Drug Administration (FDA) is racing to make coronavirus tests more widely available. Our Food, Drug & Device/FDA Team examines how the FDA is using its authority to issue emergency use authorizations (EUAs) to approve new tests and testing facilities.

  • How labs can leverage the CDC’s EUA
  • Ways labs can apply for their own EUAs
  • Implications of the policy for commercial manufacturers

To accelerate availability of diagnostic tests for SARS-CoV-2 (the virus that causes COVID-19), the Food and Drug Administration (FDA) continues to utilize its authority to permit diagnostic tests on the market via emergency use authorization (EUA). Most recently, on March 21, 2020, the FDA issued its first EUA for a point of care diagnostic that provides results to patients within hours, without the need to send samples to a laboratory. The Cepheid point of care test is indicated for the qualitative detection of nucleic acid from SARS-CoV-2. The EUA granted to the Cepheid Xpert Xpress SARS-CoV-2 test represents another milestone in the FDA’s efforts to respond to the rapidly evolving coronavirus pandemic.

On March 16, in a revised version of its Policy for Diagnostics Testing in Laboratories Certified to Perform High-Complexity Testing Under CLIA Prior to Emergency Use Authorization for Coronavirus Disease-2019 During the Public Health Emergency, (the “Guidance,” originally issued February 29), the FDA announced that it is permitting labs that are certified to perform high-complexity testing under Clinical Laboratory Improvement Amendments (CLIA) and comply with CLIA requirements to utilize validated nucleic acid or serological assay tests after notifying the FDA of completed validation. The FDA recommends that the lab submit an EUA request for nucleic-acid-based tests to the FDA within 15 business days after initial notification to the FDA.

Following the announcement of a public health emergency by the Secretary of Health and Human Services (HHS), the FDA first exercised its authority to bring diagnostics to the market on an emergency basis on February 4, 2020, when the FDA authorized an EUA for the Centers for Disease Control and Prevention’s (CDC) 2019-nCoV Real-Time RT-PCR Diagnostic Panel for the presumptive qualitative detection of nucleic acid from the coronavirus in upper and lower respiratory specimens. The CDC granted other entities seeking an EUA a right of reference to the performance data contained in its request for an EUA.

In tandem with the issuance of the CDC EUA, the FDA stated in an FAQ that clinical laboratories were not required to apply for their own EUAs if the clinical laboratories: (1) are certified to perform high-complexity testing under CLIA; (2) purchase CDC-qualified lots of SARS-CoV-2 test kit reagents; and (3) follow the CDC protocol exactly. In the FAQs, the FDA further clarified that certain other extraction platforms and detection instruments can be substituted for those specified in the CDC EUA without additional validation or the FDA review (i.e., no bridging studies are needed). The FDA has also stated in the FAQs that if a lab’s method is similar to the CDC’s, but the differences are not identified in the FAQ as permitted variations, the lab may use bridging studies in lieu of complete revalidation.

If a lab opts to utilize its test before the FDA authorization of the EUA, the requestor must send the first five positive and first five negative clinical specimens tested to another lab for confirmatory testing that uses an EUA-authorized test. Test reports should indicate that “the test has been validated but the FDA’s independent review of this validation is pending.” If the FDA is ultimately unable to authorize the EUA, or if confirmatory testing provides contradictory results from those reached using the test under review, testing must stop and corrected test reports indicating that the test may not be valid must be issued. A list of labs that have notified the FDA that they have validated a COVID-19 test and have begun testing is provided in the FAQs.

Since the CDC EUA authorized on February 4, the FDA has authorized an additional 12 EUAs for diagnostic tests not covered by the CDC EUA.

The March 16 Guidance also provides for serology-based tests to be used without submitting an EUA, but test reports must include statements that: (1) the “test has not been reviewed by the FDA”; (2) “negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals”; (3) “Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status”; and (4) “Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.”

Companies manufacturing diagnostic tests may market diagnostic tests for SARS-CoV-2 in the same manner, and under the same limitations, as those tests developed by CLIA high-complexity labs except that: (1) the tests may be used at labs or by health care providers, while tests developed by CLIA high-complexity labs may only be used at the lab where the test was developed; and (2) nucleic-acid-based tests developed for commercial distribution need not be confirmed by labs using an EUA-authorized method. Lists of companies taking advantage of the policy for nucleic-acid- and serology-based tests can be found in the FAQs.

Finally, under the March 16 Guidance, states or territories may take sole responsibility to regulate SARS-CoV-2 tests developed by CLIA-certified labs regulated by the state or territory. This extends the enforcement discretion that the FDA afforded the New York State Department of Health (NYSDOH) on March 12 and the President’s subsequent Memorandum on Expanding State-Approved Diagnostic Tests directing the FDA to extend the enforcement discretion to all states and territories. The FDA would not review an EUA request – authorization for the use of the tests would be under state law and using procedures developed by the state. However, the FDA does expect the tests to be validated. The FDA is requesting that states or territories notify it when they decide to self-regulate tests developed by CLIA-certified labs regulated by the state or territory. The FDA is also requesting that labs alert the FDA when they begin testing and what their testing capacity is. A list of states opting to self-regulate SARS-CoV-2 diagnostic tests can be found in the FAQs.

The FDA has made numerous attempts to expedite the introduction of diagnostic tests to the market. For instance, the FDA indicated that it completed its review of the first two commercial test EUAs within 24 hours of receiving the requests and allowed some of these tests to be shipped before receipt of the EUAs. The FDA also held a virtual town hall on March 6 to discuss a prior iteration of the policy, released February 29, and to field questions from diagnostic test developers. The FDA has indicated that it will work collaboratively with any requestor to address any potential concerns or safety considerations raised during the review of the EUA request. In addition, the FDA has established a 24-hour toll-free line, 1-888-INFO-FDA, to assist test developers.

To date, there have been no EUAs issued for diagnostic tests intended for home use. On March 20, the FDA issued a statement, FDA Alerts Consumers About Unauthorized Fraudulent COVID-19 Test Kits, addressing the marketing of diagnostic test kits marketed for use in the home. The FDA indicates that the marketing of diagnostic test kits without appropriate FDA oversight can pose serious health risks by causing some patients to delay or forgo appropriate treatment. The FDA further states that enforcement action, similar to the joint action it took with the Federal Trade Commission (FTC) on March 9, will be taken against those illegally marketing SARS-CoV-2 diagnostic tests. Further actions including seizures and injunctions may also be considered.

While the FDA has extended considerable leeway to labs and manufacturers in the marketing and use of diagnostic tests for SARS-CoV-2, we expect the FDA to take decisive action against any entity putting patient or caregiver health at risk for personal gain.

Implications of the Policy for Commercial Manufacturers

The global COVID-19 pandemic requires a massive and coordinated response. Accelerating market access for tests developed by commercial manufacturers will greatly expand availability of tests. We note, however, that because the FDA is not undertaking a full review of these tests, and is waiving quality system regulation (QSR) requirements for manufacturers during the duration of the EUA, issues related to design flaws or manufacturing issues may not be readily apparent. Moreover, with its recent announcements on postponing inspections (Alston & Bird advisories on the topic can be found here and here), the FDA will not have its usual means of ensuring that manufacturers are meeting their regulatory obligations. While the FDA may request documents in lieu of inspection, if a test is shown to be ineffective, the FDA could conduct a for-cause inspection and/or take enforcement action.

Background on EUAs

EUAs are authorized and regulated under Section 564 of the Federal Food, Drug, and Cosmetic Act (FFDCA). EUAs can be authorized if an emergency is declared by at least one of four federal entities, including HHS, the parent agency of the FDA, and the Secretary of HHS has determined that: (1) the “biological, chemical, radiological, or nuclear agent or agents [BCRNAs] … can cause a serious or life-threatening disease or condition”; (2) the available evidence suggests that “it is reasonable to believe that the product may be effective in diagnosing, treating, or preventing” either “such disease or condition; or a serious or life-threatening disease or condition caused by a product authorized under [the FFDCA] for diagnosing, treating, or preventing such a disease or condition caused by such an agent”; (3) the benefits of the product outweigh the risks, taking into account the threat from the BRCNA; and (4) “that there is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating such disease or condition.”


In the past week, the FDA’s efforts to address the shortage of diagnostic tests has accelerated considerably. The FDA is now moving quickly, under what it describes as an “unprecedented policy,” to allow a much broader set of diagnostic tests onto the market for emergency use. At the same time, the FDA has started taking enforcement action against bad actors that are attempting to market fraudulent test kits. These recent developments suggest that the FDA will continue to adapt and respond to meet the needs of health care providers and patients to address the demands resulting from the coronavirus pandemic.

Download PDF of Advisory

[View source.]


Written by:

Alston & Bird

Alston & Bird on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.